Clinical Trials

Numerous clinical trials spanning early to late phases evaluate Eltrombopag across a range of hematologic and infectious conditions, primarily primary immune thrombocytopenia, severe aplastic anemia, myelodysplastic syndrome, acute myeloid leukemia, and hepatitis C-associated thrombocytopenia. Sponsored by pharmaceutical leaders such as Novartis alongside academic medical centers and cooperative groups—including M.D. Anderson Cancer Center and the French Innovative Leukemia Organisation—these studies exhibit diverse recruitment statuses, including active, completed, and terminated.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07660172 NOT_YET_RECRUITING
Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
 2027-02-08 PHASE2
NCT04518475 RECRUITING
Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China
 2020-08-10 PHASE4
NCT07558434 NOT_YET_RECRUITING
Severe Aplastic Anemia (SAA); Transfusion-dependent Non-severe Aplastic Anemia
Peking Union Medical College Hospital
 2026-04 PHASE2
NCT07523009 WITHDRAWN
Severe Aplastic Anemia (SAA); Transfusion-dependent Non-severe Aplastic Anemia
Peking Union Medical College Hospital
 2026-06 PHASE2
NCT07113743 ENROLLING_BY_INVITATION
Chronic Granulomatous Disease (CGD)
National Institute of Allergy and Infectious Diseases (NIAID)
 2025-09-10 PHASE1; PHASE2
NCT06493981 NOT_YET_RECRUITING
Aplastic Anemia Idiopathic
Assiut University
 2024-07 PHASE3
NCT06630221 SUSPENDED
Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia
Abhay Singh, MD MPH
 2025-06-17 PHASE2
NCT07476846 NOT_YET_RECRUITING
Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China
 2026-06
NCT06790888 NOT_YET_RECRUITING
ITP - Immune Thrombocytopenia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
 2025-02
NCT07189910 NOT_YET_RECRUITING
Primary Immune Thrombocytopenia (ITP)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
 2025-12-01 PHASE4
NCT07788456 RECRUITING
ITP - Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
 2026-06-22 PHASE4
NCT06345495 RECRUITING
Splenomegaly; Myelofibrosis
M.D. Anderson Cancer Center
 2024-10-01 PHASE2
NCT07687134 NOT_YET_RECRUITING
Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
 2026-07-10 PHASE2
NCT07001397 NOT_YET_RECRUITING
Aplastic Anemias
Peking Union Medical College Hospital
 2025-06-23 PHASE3
NCT07093606 RECRUITING
ITP - Immune Thrombocytopenia
Sohag University
 2025-07-14
NCT06479291 RECRUITING
Immune Thrombocytopenia With Positive ANA Antibodies
Yunfeng Cheng
 2024-07
NCT03844360 RECRUITING
Hematological Neoplasms
Wei Zhao
 2016-01-31 PHASE4
NCT06607367 NOT_YET_RECRUITING
Poor Graft Function; Aplastic Anemia Idiopathic
Melbourne Health
 2024-10-30 PHASE1; PHASE2
NCT06834451 ACTIVE_NOT_RECRUITING
Healthy; Healthy Donors
Centro de Atencion e Investigacion Medica
 2025-06-01 PHASE4
NCT06531018 RECRUITING
Primary Immune Thrombocytopenia
Renata PLC
 2025-02-07 PHASE1; PHASE2
NCT03206086 ACTIVE_NOT_RECRUITING
Fanconi Anemia
National Heart, Lung, and Blood Institute (NHLBI)
 2018-11-02 PHASE2
NCT05466201 COMPLETED
Stem Cell Transplant Complications
The First Affiliated Hospital of Soochow University
 2022-10-22 PHASE2; PHASE3
NCT05653219 ACTIVE_NOT_RECRUITING
Primary Immune Thrombocytopenia
Novartis Pharmaceuticals
 2023-02-02 PHASE3
NCT05369377 UNKNOWN
Immune Thrombocytopenia
Peking University People's Hospital
 2022-06-01 PHASE2
NCT04485416 SUSPENDED
Solid Tumor, Childhood; Solid Tumor
University of California, Davis
 2021-07-16 PHASE1
NCT04797000 ACTIVE_NOT_RECRUITING
Myelodysplastic Syndromes
Novartis Pharmaceuticals
 2021-05-25 PHASE2
NCT04600960 RECRUITING
Chemotherapy-induced Thrombocytopenia; Eltrombopag
Institute of Hematology & Blood Diseases Hospital, China
 2020-12-31 PHASE2
NCT05961410 RECRUITING
Lymphoma; Peripheral Blood Stem Cell Transplantation
National Taiwan University Hospital
 2023-08-15 PHASE2
NCT02773225 COMPLETED
Anemia, Aplastic
B. Höchsmann
 2015-01-27 PHASE2; PHASE3
NCT04304820 RECRUITING
Severe Aplastic Anemia
National Heart, Lung, and Blood Institute (NHLBI)
 2020-05-07 PHASE2
NCT05438875 COMPLETED
Purpura, Thrombocytopenic, Idiopathic
Peking University People's Hospital
 2022-10-12 PHASE3
NCT04993885 RECRUITING
Immune Thrombocytopenia; Autoantibodies; Evan Syndrome; Connective Tissue Diseases
Institute of Hematology & Blood Diseases Hospital, China
 2021-09-01 PHASE2
NCT03939637 COMPLETED
Immune Thrombocytopenia
Baylor College of Medicine
 2019-05-02 PHASE3
NCT04812483 COMPLETED
Primary Immune Thrombocytopenia (ITP)
University Children's Hospital Basel
 2022-09-01 PHASE2
NCT05583838 COMPLETED
Previously Treated Primary Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
 2022-11-22 PHASE4
NCT05861297 UNKNOWN
Immune Thrombocytopenia Purpura
Nahda University
 2020-05-05 PHASE4
NCT04638829 COMPLETED
Immune Thrombocytopenia
Sobi, Inc.
 2021-03-15 PHASE4
NCT04346654 COMPLETED
Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
 2020-10-09 PHASE2
NCT04542382 COMPLETED
Healthy Volunteers
University of California, San Francisco
 2021-10-28 PHASE1
NCT05924152 COMPLETED
Healthy Adults
Mirati Therapeutics Inc.
 2023-06-29 PHASE1
NCT05961410 Recruiting
Lymphoma|Peripheral Blood Stem Cell Transplantation
National Taiwan University Hospital|Novartis
 2023-08-15 Phase 2
NCT03638817 COMPLETED
Thrombocytopenia
University Hospital, Toulouse
 2019-08-02 PHASE2
NCT06045052 COMPLETED
Fanconi Anemia
Julian Sevilla
 2020-12-02 PHASE2
NCT01927731 COMPLETED
Bone Marrow Transplantation Recipient; Cord Blood Transplant Recipient; Hematopoietic Cell Transplantation Recipient
M.D. Anderson Cancer Center
 2013-10-14 PHASE2
NCT06768619 COMPLETED
Thrombocytopenia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 2023-03-20
NCT05286164 UNKNOWN
CART Treatment; B Cell Lymphoma
Tel-Aviv Sourasky Medical Center
 2022-04 PHASE2
NCT03948529 TERMINATED
Leukemia; Graft Failure
University Hospital, Lille
 2019-09-05 PHASE2
NCT05653219 Recruiting
Primary Immune Thrombocytopenia
Novartis Pharmaceuticals|Novartis
 2023-01-21 Phase 3
NCT03830749 COMPLETED
Immune Thrombocytopenia
Humanity & Health Medical Group Limited
 2018-07-01 PHASE2
NCT04371939 UNKNOWN
Wiskott-Aldrich Syndrome
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
 2019-11-05 PHASE2
NCT03413306 UNKNOWN
Acquired Aplastic Anemia
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
 2016-12-10 PHASE3
NCT04269889 COMPLETED
Anemia, Diamond-Blackfan
National Heart, Lung, and Blood Institute (NHLBI)
 2020-12-01 PHASE1; PHASE2
NCT04403321 COMPLETED
Aplastic Anemia; Drug Effect
Peking Union Medical College Hospital
 2020-07-01 PHASE2
NCT03664518 COMPLETED
Thrombocytopenia Purpura; Chronic HBV Infection
Institute of Hematology & Blood Diseases Hospital, China
 2018-12-04 PHASE2
NCT03603795 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia
French Innovative Leukemia Organisation
 2018-10-11 PHASE2
NCT04328727 COMPLETED
Severe Aplastic Anemia (SAA)
Novartis Pharmaceuticals
 2020-11-04 PHASE2
NCT03025698 COMPLETED
Aplastic Anemia
Novartis Pharmaceuticals
 2017-09-30 PHASE2
NCT01168921 COMPLETED
CLL; Leukemia
M.D. Anderson Cancer Center
 2010-11-03 PHASE2
NCT01957176 COMPLETED
Thrombocytopaenia
Novartis Pharmaceuticals
 2013-10-15 PHASE4
NCT01428635 COMPLETED
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Primary Myelofibrosis; Thrombocytopenia
M.D. Anderson Cancer Center
 2012-01-13 PHASE2; PHASE3
NCT04917679 COMPLETED
Thrombocytopenia
Qilu Hospital of Shandong University
 2020-09-01 PHASE2
NCT04518878 UNKNOWN
Immune Thrombocytopenia
Peking University People's Hospital
 2020-08-31 PHASE1
NCT03524612 COMPLETED
Immune Thrombocytopenic Purpura (ITP)
Novartis Pharmaceuticals
 2018-11-02 PHASE2
NCT05049668 Enrolling by invitation
Severe Aplastic Anemia
European Society for Blood and Marrow Transplantation
 2021-10 --
NCT03412188 COMPLETED
Idiopathic Thrombocytopenic Purpura
Nayera Hazaa Elsherif
 2018-08-01
NCT03515096 COMPLETED
Eltrombopag; Hematopoietic Stem Cell Transplantation; Thrombocytopenia
Shenzhen Second People's Hospital
 2018-07-01 PHASE3
NCT04516837 UNKNOWN
Immune Thrombocytopenia
Peking University People's Hospital
 2020-08-31 PHASE2
NCT03988608 COMPLETED
Aplastic Anemia
Novartis Pharmaceuticals
 2019-12-09 PHASE2
NCT02446145 TERMINATED
Acute Myeloid Leukemia
Technische Universität Dresden
 2015-05 PHASE2
NCT02099747 COMPLETED
Severe Aplastic Anemia
European Society for Blood and Marrow Transplantation
 2015-07 PHASE3
NCT02998645 COMPLETED
Severe Aplastic Anemia
Novartis Pharmaceuticals
 2017-05-11 PHASE2
NCT03718533 TERMINATED
Poor Graft Function
Novartis Pharmaceuticals
 2018-12-17 PHASE2
NCT04102033 UNKNOWN
Immune Thrombocytopenia
Assiut University
 2019-11-01 PHASE4
NCT04289207 UNKNOWN
Immune Thrombocytopenia
Seoul National University Hospital
 2020-03-01 PHASE2
NCT01772420 COMPLETED
Adult Myelodysplastic Syndrome; Anemia; Chronic Myelomonocytic Leukemia
Albert Einstein College of Medicine
 2012-10 PHASE2
NCT01791101 COMPLETED
Thrombocytopenia
Gruppo Italiano Malattie EMatologiche dell'Adulto
 2013-09-16 PHASE2
NCT03754634 COMPLETED
Thrombocytopenia
Shandong University
 2019-05-01 PHASE2
NCT03771378 UNKNOWN
Primary Immune Thrombocytopenia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
 2019-01-16 PHASE4
NCT06768632 COMPLETED
Thrombocytopenia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 2020-01-02
NCT03243656 COMPLETED
Eltrombopag
Assiut University
 2017-12-20 PHASE4
NCT03701217 UNKNOWN
Eltrombopag; Thrombocytopenia; Acute Myeloid Leukemia
Nanfang Hospital, Southern Medical University
 2018-09-10 PHASE2; PHASE3
NCT01621204 COMPLETED
Immune Thrombocytopenic Purpura
McMaster University
 2012-10 PHASE3
NCT02093325 UNKNOWN
Solid Tumor
Chang Gung Memorial Hospital
 2014-03 PHASE3
NCT01893372 COMPLETED
Leukemia
M.D. Anderson Cancer Center
 2013-10 PHASE2
NCT02010645 TERMINATED
Leukemia
M.D. Anderson Cancer Center
 2014-03 PHASE2
NCT03437603 UNKNOWN
Poor Graft Function
The First Affiliated Hospital of Soochow University
 2018-02 PHASE2
NCT02323178 COMPLETED
CMML; Thrombocytopenia
Groupe Francophone des Myelodysplasies
 2014-08-07 PHASE1; PHASE2
NCT02071901 COMPLETED
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia
Case Comprehensive Cancer Center
 2014-08-14 PHASE2
NCT02928419 TERMINATED
Myelodysplastic Syndromes
Associazione Qol-one
 2015-05 PHASE2
NCT01610180 COMPLETED
Purpura, Thrombocytopenic, Idiopathic; Autoimmune Thrombocytopenic Purpura; Autoimmune Thrombocytopenia; Chronic Lymphocytic Leukemia; Non Hodgkin's Lymphoma
Fondazione Progetto Ematologia
 2012-06 PHASE2
NCT02402998 COMPLETED
Primacy Immune Thrombocytopenia
Gruppo Italiano Malattie EMatologiche dell'Adulto
 2016-02-24 PHASE2
NCT01000051 COMPLETED
Thrombocytopenia
M.D. Anderson Cancer Center
 2010-02-17 PHASE2
NCT01328587 COMPLETED
Moderate Aplastic Anemia; Unilineage Bone Marrow Failure Disorders
National Heart, Lung, and Blood Institute (NHLBI)
 2012-03-13 PHASE2
NCT02422394 COMPLETED
Inherited Platelet Disorder
Fondazione IRCCS Policlinico San Matteo di Pavia
 2015-04 PHASE2
NCT01623167 ACTIVE_NOT_RECRUITING
Severe Aplastic Anemia
National Heart, Lung, and Blood Institute (NHLBI)
 2012-07-02 PHASE1; PHASE2
NCT01286038 TERMINATED
Myelodysplastic Syndrome (MDS); Thrombocytopenia
H. Lee Moffitt Cancer Center and Research Institute
 2011-04-06 PHASE1
NCT01891994 COMPLETED
Severe Aplastic Anemia (SAA)
National Heart, Lung, and Blood Institute (NHLBI)
 2013-06-28 PHASE2
NCT00961064 COMPLETED
Myelodysplastic Syndromes; Thrombocytopenia
National Heart, Lung, and Blood Institute (NHLBI)
 2011-03-15 PHASE2
NCT02201290 COMPLETED
Purpura, Thrombocytopenic, Idiopathic
Novartis Pharmaceuticals
 2013-06-18 PHASE3
NCT02877212 UNKNOWN
Immune Thrombocytopenic Purpura (ITP)
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
 2016-07 PHASE3
NCT00909363 TERMINATED
Wiskott-Aldrich Syndrome; Thrombocytopenia; Bleeding
Weill Medical College of Cornell University
 2009-06 PHASE2
NCT02834286 UNKNOWN
Immune Thrombocytopenia
Hospital Universitario Dr. Jose E. Gonzalez
 2015-03 PHASE2
NCT01880047 COMPLETED
Immune Thrombocytopenia; Platelet Disorder
Weill Medical College of Cornell University
 2013-02 PHASE2
NCT02912208 ACTIVE_NOT_RECRUITING
Myelodysplastic Syndromes; Thrombocytopenia
Associazione Qol-one
 2011-06-11 PHASE2
NCT01286675 COMPLETED
Multiple Myeloma
Dana-Farber Cancer Institute
 2011-03 EARLY_PHASE1
NCT02404025 COMPLETED
Aplastic Anemia
Novartis Pharmaceuticals
 2015-05-12 PHASE2
NCT01757145 UNKNOWN
Hematological Malignancy; Bone Marrow Failure Syndrome
Rabin Medical Center
 2013-01 PHASE2
NCT01703169 COMPLETED
Severe Aplastic Anemia; Very Severe Aplastic Anemia; Moderate Aplastic Anemia
University of Utah
 2012-11 PHASE2
NCT01940562 UNKNOWN
Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation.
moshe yeshurun
 2013-10 PHASE2
NCT02158936 TERMINATED
Thrombocytopaenia
Novartis Pharmaceuticals
 2014-06-10 PHASE3
NCT01656252 TERMINATED
Acute Myeloid Leukemia
PrECOG, LLC.
 2012-07 PHASE1; PHASE2
NCT00903929 COMPLETED
Thrombocytopenia; Acute Radiation Syndrome
Jane Liesveld
 2009-12 PHASE1
NCT02148133 COMPLETED
Cytopaenia
Novartis Pharmaceuticals
 2014-07-23 PHASE2
NCT00902018 COMPLETED
Immune Thrombocytopenia
Weill Medical College of Cornell University
 2009-01 PHASE2
NCT00351468 COMPLETED
Purpura, Thrombocytopaenic, Idiopathic
Novartis Pharmaceuticals
 2006-06 PHASE3
NCT01821625 TERMINATED
Thrombocytopenia; Hepatitis C
University of Texas Southwestern Medical Center
 2013-04 PHASE2; PHASE3
NCT01890746 COMPLETED
Acute Leukaemia
Novartis Pharmaceuticals
 2013-09-05 PHASE2
NCT01440374 COMPLETED
Thrombocytopaenia
Novartis Pharmaceuticals
 2011-09 PHASE2
NCT01147809 COMPLETED
Thrombocytopaenia
GlaxoSmithKline
 2010-06 PHASE2
NCT02281370 COMPLETED
Purpura, Thrombocytopenic, Idiopathic
GlaxoSmithKline
 2014-11-05 PHASE1
NCT01550185 TERMINATED
Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Roswell Park Cancer Institute
 2012-05 PHASE1
NCT02254434 COMPLETED
Cirrhosis, Liver
GlaxoSmithKline
 2014-08-28 PHASE1
NCT01484314 TERMINATED
Thrombocytopenia; Multiple Myeloma
Dana-Farber Cancer Institute
 2012-04 PHASE2
NCT01055600 WITHDRAWN
Thrombocytopaenia
GlaxoSmithKline
 2013-03 PHASE4
NCT01762761 COMPLETED
Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
Novartis Pharmaceuticals
 2013-02-18 PHASE3
NCT01098487 COMPLETED
Purpura, Thrombocytopaenic, Idiopathic
GlaxoSmithKline
 2010-05 PHASE4
NCT01488565 COMPLETED
Myelodysplastic Syndromes (MDS); Acute Myeloid Leukaemia (AML)
Peter MacCallum Cancer Centre, Australia
 2010-12 PHASE2
NCT00908037 COMPLETED
Purpura, Thrombocytopaenic, Idiopathic
GlaxoSmithKline
 2009-09-30 PHASE2
NCT01520909 COMPLETED
Idiopathic Thrombocytopenic Purpura
GlaxoSmithKline
 2012-03 PHASE3
NCT01397149 TERMINATED
Chronic Lymphocytic Leukemia; Thrombocytopenia
University of Ulm
 2011-10 PHASE1; PHASE2
NCT01433978 TERMINATED
Idiopathic Thrombocytopenic Purpura
Eisai Inc.
 2012-03-26 PHASE3
NCT01652599 COMPLETED
Immune Thrombocytopenic Purpura
Hospital Universitario Dr. Jose E. Gonzalez
 2012-06 PHASE2
NCT00922883 COMPLETED
Anemia, Aplastic; Anemia, Hypoplastic; Thrombocytopenia
National Heart, Lung, and Blood Institute (NHLBI)
 2009-05-29 PHASE2
NCT01481220 COMPLETED
Myelodysplastic Syndrome; Thrombocytopenia
Nordic MDS Group
 2011-10 PHASE1
NCT01500538 TERMINATED
Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma
Peter MacCallum Cancer Centre, Australia
 2012-10 PHASE2
NCT01113502 TERMINATED
Acute Myelogenous Leukemia (AML)
Abramson Cancer Center at Penn Medicine
 2010-06 PHASE1; PHASE2
NCT01491594 TERMINATED
Sarcoma, Soft Tissue; Osteosarcoma; Neoplasms, Connective and Soft Tissue
Duke University
 2012-04 PHASE1
NCT00996216 COMPLETED
Hepatitis C
GlaxoSmithKline
 2009-09 PHASE3
NCT01657552 COMPLETED
Thrombocytopaenia
GlaxoSmithKline
 2012-08-01 PHASE1
NCT00903422 COMPLETED
Myelodysplastic Syndrome
GlaxoSmithKline
 2009-05-14 PHASE1
NCT01194167 WITHDRAWN
Thrombocytopenia
University of Cincinnati
 2010-08 PHASE2
NCT00529568 COMPLETED
Hepatitis C, Chronic
GlaxoSmithKline
 2007-10 PHASE3
NCT00516321 COMPLETED
Hepatitis C, Chronic
GlaxoSmithKline
 2007-10 PHASE3
NCT00888901 COMPLETED
Idiopathic Thrombocytopenic Purpura
Ingrid Pabinger, MD
 2009-05 PHASE4
NCT00828750 COMPLETED
Idiopathic Thrombocytopenic Purpura; Purpura, Thrombocytopenic, Idiopathic
GlaxoSmithKline
 2008-05 PHASE3
NCT00358540 COMPLETED
Thrombocytopaenia
GlaxoSmithKline
 2006-06-01 PHASE1
NCT01133860 COMPLETED
Blood Platelet Disorders
Fondazione IRCCS Policlinico San Matteo di Pavia
 2009-01 PHASE2
NCT01072162 COMPLETED
Purpura, Thrombocytopaenic, Idiopathic
GlaxoSmithKline
 2010-01-12 PHASE1
NCT00678587 TERMINATED
Non-alcoholic Steatohepatitis; Chronic Liver Disease; HCV; NASH - Nonalcoholic Steatohepatitis; HIV Infection; Thrombocytopenia; Hepatitis C Virus; HBV; Human Immunodeficiency Virus; Liver Diseases; Hepatitis B Virus
GlaxoSmithKline
 2008-06 PHASE3
NCT00861601 COMPLETED
Liver Diseases
GlaxoSmithKline
 2009-01 PHASE2
NCT00833378 COMPLETED
Hepatitis C
GlaxoSmithKline
 2009-01-19 PHASE1
NCT00688272 COMPLETED
Purpura, Thrombocytopaenic, Idiopathic
GlaxoSmithKline
 2008-06-02 PHASE1
NCT00424177 COMPLETED
Purpura, Thrombocytopaenic, Idiopathic
GlaxoSmithKline
 2007-03 PHASE2
NCT00370331 COMPLETED
Purpura, Thrombocytopaenic, Idiopathic
GlaxoSmithKline
 2006-11 PHASE3
NCT00442871 COMPLETED
Purpura, Thrombocytopaenic, Idiopathic
GlaxoSmithKline
 2006-09-28 PHASE1
NCT00359463 COMPLETED
Purpura, Thrombocytopaenic, Idiopathic
GlaxoSmithKline
 2006-04-18 PHASE1
NCT00487968 COMPLETED
Healthy Subjects; Purpura, Thrombocytopenic, Idiopathic
GlaxoSmithKline
 2007-05 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-06-25)

Check the Eltrombopag (SB-497115) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Eltrombopag functions as a selective, nonpeptide small-molecule agonist that binds to the transmembrane domain of the thrombopoietin receptor, initiating downstream signal transduction through the STAT, AKT, and MAPK pathways. This activation drives the proliferation and differentiation of megakaryocytes, thereby promoting platelet production to treat cytopenias in patients with primary immune thrombocytopenia, severe aplastic anemia, and hepatitis C-associated thrombocytopenia.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.